Foamy urine could have a normal cause like rapid urination. But if it happens frequently, it could be caused by a medical ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial presented during a ...

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...

Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Everest Medicines presents positive results in preliminary analysis of phase 1b/2a trial of novel BTK inhibitor EVER001 at ERA 2025 Congress: Shanghai, China Tuesday, June 10, 202 ...

Depending on more exact details of your kidney function (especially whether you are losing protein in your urine), ...